If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-07. Where a claim depends on a specific study, the study is described rather than over-claimed.
The material is commonly handled as a lyophilized powder in sealed vials. The solid dissolves readily in water and in polar organic solvents, producing a clear solution after reconstitution. Light, heat and repeated freeze-thaw cycles are the concerns most often raised in handling guidance, because peptide bonds and the constrained ring can degrade. Working solutions are generally prepared fresh, and material left in solution is treated as less stable than the dry form. These properties shape how laboratories store and aliquot reference material.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography with ultraviolet detection, often paired with mass spectrometry. Retention time supports identity, while the mass spectrum confirms the molecular weight of the intact peptide. Purity is frequently reported as a percentage of total peak area, a figure that depends on the wavelength, column and gradient used. Impurity profiling may also look for truncated sequences, oxidised forms and residual counterions. Amino acid analysis and peptide mapping provide orthogonal confirmation when required.
Regulatory status varies by jurisdiction, and the substance is frequently described as unapproved for therapeutic use. Some authorities classify it alongside prescription-only medicines or controlled categories, while others address it through general consumer protection rules. Analytical surveys have reported mismatches between label claims and measured content in products sold online, although the scope of such testing is limited. Whether these discrepancies are widespread remains an open question. Discussion in the literature therefore tends to combine chemistry, supply-chain observation and policy analysis.
Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.
Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.
Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid in a sealed vial |
| Solubility class | Soluble in water and polar organic solvents | Reconstituted solutions are generally clear |
| Typical storage temperature | -20 degrees Celsius or below, dry | Protect from light; avoid repeated freeze-thaw cycles |
| Common analytical methods | Reversed-phase HPLC-UV, LC-MS | Used for purity estimation and mass confirmation |
| Reported purity range | Area percentage above 95 percent | Reporting practice and acceptance limits differ by laboratory |
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Melanotan-2 is a synthetic linear peptide built from seven amino acids arranged in a short chain. Its sequence is commonly written as Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-NH2, which includes a modified N-terminus and an amidated C-terminus. The molecule belongs to the melanocortin family and acts as a receptor agonist. Structural features such as the D-phenylalanine residue and the Nle substitution are associated with increased stability against enzymatic degradation relative to the natural parent peptide.
=== Animal sources === Animal-sourced foods do not generally provide much vitamin C, and what there is, is largely destroyed by heat during cooking. For example, raw chicken liver contains 17.9 mg/100 g, but fried, the content is reduced to 2.7 mg/100 g. Vitamin C is present in human breast milk at 5.0 mg/100 g. Cow's milk contains 1.0 mg/100 g, but the heat of pasteurization destroys it.
Von Willebrand factor (VWF) (German: [fɔn ˈvɪləbʁant]) is a blood glycoprotein that promotes primary hemostasis, specifically, platelet adhesion. It is deficient and/or defective in von Willebrand disease and is involved in many other diseases, including thrombotic thrombocytopenic purpura, Heyde's syndrome, and possibly hemolytic–uremic syndrome. Increased plasma levels in many cardiovascular, neoplastic, metabolic (e.g. diabetes), and connective tissue diseases are presumed to arise from adverse changes to the endothelium, and may predict an increased risk of thrombosis. Platelet adhesion is mainly mediated via interactions with VWF, which acts as a bridge between the platelet surface receptor glycoprotein Ib (GpIb) and the exposed collagen after vascular injury. Genetic deficiencies of VWF or GpIb (Bernard–Soulier syndrome) result in bleeding disorders.
There are approximately 30 records of humans killed by cone snails. Human victims suffer little pain, because the venom contains an analgesic component. Some species reportedly can kill a human in under five minutes, thus the name "cigarette snail" as supposedly one only has time to smoke a cigarette before dying. Cone snails can sting through a wetsuit with their harpoon-like radular tooth, which resembles a transparent needle. Normally, cone snails (and many species in the superfamily Conoidea) use their venom to immobilize prey before engulfing it. The venom consists of a mixture of peptides, called conopeptides. The venom is typically made up of 10 to 30 amino acids, but in some species as many as 60. The venom of each cone snail species may contain as many as 200 pharmacologically active components. It is estimated that more than 50,000 conopeptides can be found, because every species of cone snail is thought to produce its own specific venom. Cone-snail venom has come to interest biotechnologists and pharmacists because of its potential medicinal properties. Production of synthetic conopeptides has started, using solid-phase peptide synthesis. A component of the venom of Conus magus, ω-conotoxin, is now marketed as the analgesic ziconotide, which is used as a last resort in chronic and severe pain. Conopeptides are also being looked at as anti-epileptic agents and to help stop nerve-cell death after a stroke or head injury.
The International Criminal Court (ICC) opened a preliminary investigation into Duterte's drug war in 2018, prompting Duterte to withdraw the Philippines from that body in response. Duterte was arrested on March 11, 2025 and transferred to ICC custody in The Hague the next day, making him the first Philippine president to face an international tribunal and the first Asian leader to face a trial before the ICC. Despite this, he was re-elected as the mayor of Davao City in 2025; as he remains in The Hague, his son Baste is serving in his place as the acting mayor. As he failed to take his oath within the prescribed six-month period, he was disqualified from assuming office under the provisions of the Local Government Code. Duterte is scheduled to face trial for crimes against humanity on November 30, 2026.
Sources: en.wikipedia.org
=== Category:EC 2.1 (transfer one-carbon groups, Methylase) === Category:EC 2.1.1 Catechol-O-methyl transferase EC 2.1.1.6 DNA methyltransferase EC 2.1.1.72, EC 2.1.1.113, EC 2.1.1.37 Histone methyltransferase EC 2.1.1.43, EC 2.1.1.125 Category:EC 2.1.3 Aspartate transcarbamoylase EC 2.1.3.2 Ornithine transcarbamoylase EC 2.1.3.3
On 8 February 2022, Aníbal Torres was appointed as Prime Minister of Peru. Torres had previously served as the Minister of Justice. The appointment of President Pedro Castillo's fourth cabinet came in the context of an attempt to resolve a political crisis.
Parmotrema perlatum typically grows in areas with ample light, favouring neutral to slightly acidic-barked broad-leaved trees. It is commonly found on siliceous rocks and walls, as well as mossy coastal rocks, generally growing in places with moderate to strong sunlight. In the Great Smoky Mountains National Park in the United States, Parmotrema perlatum is especially abundant on branches in humid, high-elevation habitats. Similarly, in East Africa, it grows in the misty environments of inselbergs, montane forests, and Erica-dominated habitats, typically found between 1,400 and 3,100 m (4,600 and 10,200 ft) above sea level. The species is globally distributed, found in both temperate and tropical regions. It has been reported across numerous European countries including Austria, Belgium, the Czech Republic, France, Germany, Great Britain, Ireland, Italy, Luxembourg, the Netherlands, Portugal, Scandinavia, Slovakia, Spain, and Ukraine. Although it is rare in Eastern Europe, it is widely distributed in both the Asian and European parts of Russia. Beyond Europe, it is also present in Macaronesia, Africa, Australia, North America, and South America. Its Asian distribution includes India, Japan, Taiwan, and South Korea. Although it has historically been recorded in Nepal and Sri Lanka, these reports are considered tentative due to shifting species concepts and possible confusion with the lookalike Parmotrema pseudonilgherrense.
Sources: en.wikipedia.org
The dry powder is more stable during transport and storage than a solution. It also allows a known amount of material to be reconstituted at a chosen concentration.
Most certificates state a percentage derived from chromatographic peak area, alongside a mass confirmation. The exact criteria and acceptance thresholds vary between laboratories.
Dry powder is kept frozen or refrigerated and protected from light and moisture. Solutions are handled cold and used promptly to limit degradation.
No regulator in a major market has approved it for human use. It appears in research settings and in products marketed outside pharmacy channels. Legal status for personal possession varies by country.